Healio

FDA grants fast track designation to nipocalimab for adults with lupus

The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus erythematosus, according to a manufacturer press release. Nipocalimab ...
The Lancet

Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years

aDepartment of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital Heidelberg, Heidelberg 69120, Germany bDepartment of Rheumatology, University Hospital Düsseldorf, ...
Healio

Self-reported depression ‘highly prevalent’ in systemic lupus erythematosus

Almost 90% of a cohort of patients with systemic lupus erythematosus reported experiencing depression or depressive symptoms ...

aTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNE ...
ascopubs.org

Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients

Emerging multiomic profiling is providing insights into the unique molecular features of brain metastases and potential targetable pathways. Molecular analysis of metastases, whenever possible, should ...